Drugs / GSK2245035
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01480271 | May → Sep 2011 | seasonal allergic rhinitis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT03707678 | Jan → Dec 2019 | asthma | GlaxoSmithKline | Withdrawn | No outcome recorded |
| Phase 2 | NCT02833974 | Dec 2016 → Feb 2018 | asthma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT01788813 | Mar 2013 → Aug 2014 | asthma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT01607372 | Apr 2012 → Sep 2013 | allergic disease | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK2245035 | “Intranasal Dosing With GSK2245035, a TLR7 Agonist” NCT01480271 ↗ |
| Action | Activate | “TLR7 agonist” NCT01480271 ↗ |
| Modality | Small molecule | — CHEMBL4297492 ↗ |
| Route | Intranasal | “administered intranasally” NCT01480271 ↗ |
| Target | TLR7 | “TLR7 agonist” NCT01480271 ↗ |